The stock of Vtv Therapeutics Inc – Class A (NASDAQ:VTVT) registered a decrease of 2.09% in short interest. VTVT’s total short interest was 1.57M shares in December as published by FINRA. Its down 2.09% from 1.61M shares, reported previously. With 776,500 shares average volume, it will take short sellers 2 days to cover their VTVT’s short positions.

The stock increased 1.32% or $0.02 during the last trading session, reaching $1.53. About 249,856 shares traded or 6.19% up from the average. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 27.67% since December 14, 2018 and is downtrending. It has underperformed by 27.67% the S&P500.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $95.84 million. The company??s drug candidate for the treatment of Alzheimer??s disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.

More notable recent vTv Therapeutics Inc. (NASDAQ:VTVT) news were published by: Globenewswire.com which released: “vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences – GlobeNewswire” on August 06, 2019, also Seekingalpha.com with their article: “CRISPR Therapeutics and ReWalk Robotics among healthcare gainers; Aeterna Zentaris and Genocea Biosciences among losers – Seeking Alpha” published on June 07, 2019, Bizjournals.com published: “Biotech entrepreneur seeks approval of 80-acre Triad R&D campus with 1,600 jobs – Triad Business Journal” on May 29, 2019. More interesting news about vTv Therapeutics Inc. (NASDAQ:VTVT) were released by: Globenewswire.com and their article: “vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update – GlobeNewswire” published on October 30, 2019 as well as Benzinga.com‘s news article titled: “21 Stocks Moving In Friday’s Pre-Market Session – Benzinga” with publication date: January 25, 2019.

vTv Therapeutics Inc. (NASDAQ:VTVT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link